EUVIMEDEUVIMED entdecken
Crossref

Indirubin Sensitizes Prostate Cancer to Docetaxel by Inhibiting Autophagy Through the circ‐Vav3/miR‐204‐5p/MAPK1 Pathway

Minghao Zheng iD, Gan Cai, Long Ma, Xian Wu, Qian Wang iD, Zhenhua Jin, Chen Zhu, Shuaiyu Niu, Yanpei Peng, Yan Xu, Jingyuan Tang, Yunfei Wei

Journal of Biochemical and Molecular Toxicology · 2026-05 · 40 (5)

DOI: 10.1002/jbt.70884 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Biochemical and Molecular Toxicology, online erschienen am 04.05.2026. Verfasst von Minghao Zheng und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine, Nanjing, China. Hauptthemen laut MEDLINE: Docetaxel, MicroRNAs, Prostatic Neoplasms, Autophagy. Die Arbeit nennt 33 Literaturangaben. Gefördert von: TCM Science and Technology Development Project of Jiangsu, Science and Technology Program of Ili Kazakh Autonomous Prefecture, Xinjiang Uygur Autonomous Region Health Science and Technology Research Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Accumulating evidence indicates that indirubin exerts inhibitory effects on prostate cancer (PCa) progression. However, the role and underlying mechanisms of indirubin in sensitizing PCa to docetaxel remain unclear. CCK‐8 assays were initially used to determine the effect of indirubin on enhancing docetaxel sensitivity in PCa cells. Following this, the expression levels of circ‐Vav3 were quantified using quantitative real‐time PCR (RT‐qPCR) to evaluate its potential role in docetaxel resistance. Functional experiments, including flow cytometry‐based apoptosis analysis and Transwell migration/invasion assays, were conducted to assess the impact of circ‐Vav3 modulation and indirubin treatment on cell viability and behavior in response to docetaxel. Rescue experiments were subsequently performed to further confirm the regulatory effect of indirubin on circ‐Vav3. Additionally, xenograft tumor models in nude mice were utilized to evaluate the therapeutic efficacy of indirubin in vivo. Mechanistic interactions between circ‐Vav3, miR‐204‐5p, and MAPK1 were further investigated using RNA pulldown assays, luciferase reporter assays, and Western blot analyses. Indirubin enhanced the sensitivity of PCa cells to docetaxel by downregulating the expression of circ‐Vav3, which was found to be significantly upregulated in docetaxel‐resistant PCa cells. Silencing circ‐Vav3 effectively reversed this resistance, as evidenced by increased apoptosis, reduced cell migration and invasion, and decreased autophagic activity. Notably, indirubin treatment suppressed circ‐Vav3 expression and thereby restored docetaxel sensitivity both in vitro and in xenograft tumor models. Mechanistically, circ‐Vav3 acted as a competing endogenous RNA (ceRNA) by sponging miR‐204‐5p, which led to the upregulation of the autophagy‐related kinase MAPK1. Inhibition of MAPK1 effectively suppressed autophagy and re‐sensitized docetaxel‐resistant PCa cells, further confirming the critical regulatory role of the circ‐Vav3/miR‐204‐5p/MAPK1 signaling axis in mediating chemoresistance. Our findings demonstrate that circ‐Vav3 promotes docetaxel resistance in PCa by sponging miR‐204‐5p and subsequently activating MAPK1‐mediated autophagy. Indirubin effectively restores chemosensitivity by targeting this regulatory pathway, offering a promising therapeutic strategy for overcoming chemoresistance in castration‐resistant prostate cancer (CRPC).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DocetaxelMicroRNAsProstatic NeoplasmsAutophagyIndolesMitogen-Activated Protein Kinase 1RNA, NeoplasmMaleHumansAnimalsMice, NudeMiceCell Line, TumorDrug Resistance, NeoplasmMice, Inbred BALB C

Stichwörter der Autor:innen

MAPK1autophagycirc‐Vav3docetaxel resistanceindirubinmiR‐204‐5pprostate cancer

Substanzen

DocetaxelMicroRNAsindirubinIndolesMitogen-Activated Protein Kinase 1MAPK1 protein, humanRNA, Neoplasm

Autor:innen und Institutionen

  • Department of Urology, Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine, Nanjing, China.
  • Department of Urology, Nantong Hospital Affiliated to Nanjing University of Chinese Medicine, Nantong, China.
  • Department of Urology, Jiangsu Provincial Hospital of Chinese Medicine-Jiangbei Branch, Nanjing, China.
  • Department of Urology, Traditional Chinese Medicine Hospital of Ili Kazak Autonomous Prefecture, Yining, China.

ORCID-Profile: Minghao Zheng, Qian Wang

Förderung

  • TCM Science and Technology Development Project of Jiangsu
  • Science and Technology Program of Ili Kazakh Autonomous Prefecture
  • Xinjiang Uygur Autonomous Region Health Science and Technology Research Program
  • Special Project for Academic Advancement of Department Heads of Jiangsu Province Hospital of Chinese Medicine

Zitieren

APA

Zheng, M., Cai, G., Ma, L., Wu, X., Wang, Q., Jin, Z., Zhu, C., Niu, S., Peng, Y., Xu, Y., Tang, J., & Wei, Y. (2026). Indirubin Sensitizes Prostate Cancer to Docetaxel by Inhibiting Autophagy Through the circ‐Vav3/miR‐204‐5p/MAPK1 Pathway. Journal of Biochemical and Molecular Toxicology, 40(5). https://doi.org/10.1002/jbt.70884

Vancouver

Zheng M, Cai G, Ma L, Wu X, Wang Q, Jin Z, et al. Indirubin Sensitizes Prostate Cancer to Docetaxel by Inhibiting Autophagy Through the circ‐Vav3/miR‐204‐5p/MAPK1 Pathway. Journal of Biochemical and Molecular Toxicology. 2026;40(5). doi:10.1002/jbt.70884

BibTeX
@article{Zheng2026,
  author = {Zheng, Minghao and Cai, Gan and Ma, Long and Wu, Xian and Wang, Qian and Jin, Zhenhua and Zhu, Chen and Niu, Shuaiyu and Peng, Yanpei and Xu, Yan and Tang, Jingyuan and Wei, Yunfei},
  title = {Indirubin Sensitizes Prostate Cancer to Docetaxel by Inhibiting Autophagy Through the circ‐Vav3/miR‐204‐5p/MAPK1 Pathway},
  journal = {Journal of Biochemical and Molecular Toxicology},
  year = {2026},
  volume = {40},
  number = {5},
  doi = {10.1002/jbt.70884}
}
Kostenlos starten →